Sign In
Buy ACOR
$0.661
+0 (+0%)
At Close: Jul 10, 2024
Acorda Therapeutics (ACOR) Sees Hammer Chart Pattern: Time to Buy?
06:50am, Wednesday, 24'th Feb 2021
Acorda Therapeutics (ACOR) has been struggling lately, but the selling pressure may be coming to an end soon.
Acorda (ACOR) to Report Q4 Earnings: What's in the Cards?
01:39pm, Monday, 08'th Feb 2021
During Acorda's (ACOR) upcoming Q4 earnings call, investor focus will be on the sales uptake of its Parkinson's disease drug, Inbrija.
Acorda (ACOR) Soars on Sale of Manufacturing Unit for Inbrija
01:33pm, Thursday, 14'th Jan 2021
Acorda (ACOR) inks an agreement to sell its Inbrija manufacturing operations in Chelsea for $80 million to Catalent. The company also announces a corporate restructuring plan to save costs.
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has entered into a definitive agreement to sell its INBRIJA manufacturing operations in Chelsea, Massac
Acorda Therapeutics to Present at 39th Annual J.P. Morgan Health Care Conference
04:07pm, Tuesday, 12'th Jan 2021
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Health Care
Acorda Therapeutics to Present at H.C. Wainwright BIOCONNECT Virtual Conference
04:20pm, Monday, 11'th Jan 2021
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., President and Chief Executive Officer, will present during the January 11th -14th H.C. Wainwrig
Acorda Therapeutics Announces Completion of One-for-Six Reverse Stock Split
04:19pm, Thursday, 31'st Dec 2020
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has completed the previously announced 1-for-6 reverse stock split of its outstanding and authorized sh
Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q3 2020 Results - Earnings Call Transcript
08:15pm, Tuesday, 03'rd Nov 2020
Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q3 2020 Results - Earnings Call Transcript
Acorda Therapeutics: Q3 Earnings Insights
04:17pm, Tuesday, 03'rd Nov 2020
Shares of Acorda Therapeutics (NASDAQ:ACOR) increased 8.33% after the company reported Q3 results. Quarterly Results Earnings per share rose 50.00% over the past year to ($0.23), which beat the estima
The Daily Biotech Pulse: Gilead's Filgotinib Stumbles With FDA, J&J Laps Up Momenta In $6.5B Deal, 2 IPOs
12:00am, Wednesday, 19'th Aug 2020
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 18)
Avenue Therapeutics Inc (NASDAQ: ATXI)
Checkmate Pharmaceuticals Inc (NASDAQ: CMPI)
DarioHealth Corp (NASDAQ:...
Perceptive Advisors Launches LianBio with Multiple Strategic Alliances and Establishes Operating Platform
12:00am, Tuesday, 11'th Aug 2020
Perceptive Advisors launches LianBio with multiple strategic alliances to develop and commercialize therapeutics in China and major Asian markets.
Jubilant Radiopharma and Navidea Biopharmaceuticals Sign Binding Memorandum of Understanding for Commercialization Partnership
12:00am, Monday, 10'th Aug 2020
Jubilant Radiopharma, a business unit of Jubilant Pharma Limited and Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) announced today that both compa
U.S. Food and Drug Administration Approves Lampit® (nifurtimox) for the Treatment of Chagas Disease in Children
12:00am, Friday, 07'th Aug 2020
Bayer announced today that the United States Food and Drug Administration (FDA) has approved Lampit® (nifurtimox) for use in pediatric patients (from
Acorda Therapeutics (ACOR) Reports Q2 Loss, Tops Revenue Estimates
10:15pm, Tuesday, 04'th Aug 2020
Acorda (ACOR) delivered earnings and revenue surprises of 23.91% and 27.56%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Acorda Therapeutics: Q2 Earnings Insights
08:20pm, Tuesday, 04'th Aug 2020
Shares of Acorda Therapeutics (NASDAQ:ACOR) moved higher by 20% after the company reported Q2 results.Quarterly Results Earnings per share rose 36.36% year over year to ($0.35), which beat the estimat
